Christineh N. Sarkissian

Christineh N. Sarkissian serves as the Chief Scientific Officer at Tandem Biotherapeutics, Inc. since December 2020 and as a Science and Business Advisor at CaraVan Biologix since February 2021, where innovative allogenic iPSC-derived therapies are developed. Christineh is a member of the Scientific Advisory Board for the National PKU Alliance, the Canadian PKU Medical Working Group, and Canadian PKU and Allied Disorders Inc., contributing to the advancement of treatment guidelines for PKU patient care. Previous roles include Director of Preclinical Development at Rubius Therapeutics and work as a consultant for multiple organizations. Christineh holds a PhD in Biochemical Genetics with a focus on Drug Development from McGill University and has furthered professional development through courses at MIT xPRO and Bentley University.